3-5 years of experience
Concerned about your lack of experience? Learn More...
Employment Type:
Full time
Job Category:
Information Services
See more jobs for students and recent grads who studied:
Records Management Specialist
Biogen | Cambridge, Massachusetts
Tell Us More About Your Job Preferences
By telling us what you think of this job, we can help find jobs that match your interests. If you want to see more jobs like this, click on the smiley face. Or if this job isn't what you are looking for, click the frowny face. Learn More...

Follow This Company

Job Description

External Posting TitleRecords Management Specialist
Job DescriptionReporting to the Senior Manager, Records Methodology & Guidance, the Senior Associate II, Records Methodology and Guidance provides compliance and quality assurance support to all Biogen Global Development departments regarding the management of Global Development records throughout their lifecycle.

Additionally, the Senior Associate II works with the Senior Manager, Records Methodology & Guidance to support Global Development colleagues to develop, execute and measure records-related programs and internal controls to ensure that operations are conducted in compliance with applicable records management standards, and to ensure that Global Development and its personnel consistently adhere to the highest ethical standards and comply with applicable legal and regulatory records management requirements. He or she will support the communication and education of staff on records policies and governance.

The Senior Associate II will be a part of the organization's records management function responsible for developing and implementing the records management program for Global Development, which will include the standards, tools, processes and systems necessary to ensure records management compliance. The Senior Associate II will support workstreams and projects that deliver key strategic objectives and align with and support projects involving records management.

Because the organization's functions are themselves accountable for implementing projects and solutions for records management compliance within their functional areas, the Senior Associate II will focus on providing functional expertise for successful implementation. In addition, the Senior Associate II will share responsibility for delivering the records management vision to the organization as part of a team that interacts across Global Development.

- Provide support to Senior Manager, Records Methodology & Guidance in providing advice and expertise to all business partners on best practices in records management, serving as a Center of Excellence for Global Development.

- Provide support for program and project management support for records management projects.

- Creation and delivery of training materials/resources to support records management initiatives across Global Development
LocationCambridge, MA, US
Job CategoryRegulatory
Requisition Number31586BR
QualificationsAt least 3 years of biotech/pharmaceutical experience, specifically in the areas of interpreting regulations, guidelines and policies to create a meaningful monitoring and compliance framework in records & information management with progressively increasing responsibilities.

Technology -- ability to assess and convey to others the implications of computerizing records management processes. For example, an understanding of validation process and 21CFR Part 11 "Electronic Records, Electronic Signatures" is an important competency for this role.

Ability to interpret records management-related regulations, guidelines and policies - understand where to find and keep up-to-date with new and updated regulations, guidances and policies
EducationBachelor's degree in relevant field (e.g. business, records management, information management). Advanced degree such as Master's in Library/Information Sciences desirable.
About BiogenCorporate Overview

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis (MS), has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS). Biogen also manufactures and commercializes biosimilars of advanced biologics. Our global organization of nearly 7,000 employees is committed to a single mission: making a meaningful difference in the lives of patients with few or no treatment options.

One of the pioneers in biotechnology, Biogen was founded in 1978 and today serves patients in nearly 90 countries. Our global headquarters and R&D operations are located in Cambridge, Massachusetts, with an international headquarters in Zug, Switzerland, world-class manufacturing facilities in Research Triangle Park, North Carolina, USA and Hillerod, Denmark, and affiliate locations around the world.

Our Science

We aspire to have the greatest impact on patients and science of any biotechnology company in the history of our industry. To us, that means creating novel medicines that benefit individuals and society, and bringing new scientific understanding to diseases for which there are no adequate treatments.

For nearly two decades Biogen has led in the research and development of new therapies to treat MS, including the most prescribed oral treatment in the world. Now our research is driving revolutionary new MS treatments with the goal of reversing or even repairing damage caused by the disease. We are now applying our neurological expertise to solve some of most challenging and complex diseases of the brain, including Alzheimer's disease, Parkinson's disease, and ALS. As we uncover new insights into human biology, Biogen is employing cutting-edge technologies to discover potential treatments for rare and genetic disorders.

Biogen is revolutionizing biologics manufacturing, developing the industry's most advanced plants and processes. This expertise is used to produce both original innovative therapies and biosimilars that expand patient access to lower-cost medicines.

Our Corporate Citizenship

The same intellectual discipline and passion that drives our science is reflected in our corporate citizenship, environmental sustainability, and commitment to diversity and inclusion. As a company, we are focused on improving science education and limiting the impact of our company on the environment. In 2015, we became a carbon neutral company and ranked first place on Newsweek's 2015 Green Rankings, and we are an industry leader on the Dow Jones Sustainability World Index. Biogen was named to Science's list of Top Employers of 2015 and in 2017 received a perfect score of 100 for the fourth consecutive year on the Human Rights Campaign (HRC) Corporate Equality Index, which also named Biogen as one of its Best Places to Work.

All qualified applicants will receive consideration for employment without regard to sex, gender identity or expression, sexual orientation, marital status, race, color, national origin, ancestry, ethnicity, religion, age, veteran status, disability, genetic information or any other basis protected by federal, state or local law. Biogen is an E-Verify Employer in the United States.

Please be advised that all legitimate correspondence from a Biogen employee will come from "@biogen.com" email accounts.

About Biogen

Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company's products address diseases such as multiple sclerosis, lymphoma and rheumatoid arthritis. The Company has four products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI (natalizumab) and FUMADERM (dimethylfumarate and monoethylfumarate salts). AVONEX is used in the treatment of relapsing forms of multiple sclerosis (MS). RITUXAN is used in the treatment of relapsed or refractory low-grade or follicular, CD20-positive, and B-cell, non-Hodgkin's lymphomas (B-cell NHLs). TYSABRI is approved for the treatment of relapsing forms of MS. FUMADERM acts as an immunomudulator. It also has product candidates, such as BG-12 (acquired with the purchase of Fumapharm), ANTI-CD80 antibody/(galiximab), ANTI-CD23 antibody/(lumiliximab), Ocrelizumab/(Humanized ANTI-CD20 Antibody) and Lixivaptan.In January 2007, the Company completed the acquisition of Syntonix Pharmaceuticals, Inc. (Source: 10-K)

This company profile was created by AfterCollege and is about Biogen. This page is not endorsed by or affiliated with Biogen. For questions regarding company profiles, please email: care@aftercollege.com.